Phase 2 Steatohepatitis Clinical Trials
25 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 25 trials
Recruiting
Phase 2
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.120 enrolled17 locationsNCT07335601
Recruiting
Phase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis
Eccogene160 enrolled58 locationsNCT07288138
Recruiting
Phase 2
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
MASH - Metabolic Dysfunction-Associated SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine300 enrolled17 locationsNCT07303803
Recruiting
Phase 2
Digoxin In NASH (CODIN)
MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Phase 1Phase 2
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc99 enrolled1 locationNCT07427680
Recruiting
Phase 2
A Study of CS060380 Tablets in Patients With MASH and Obesity
Metabolic dysfunction-associated steatohepatitis (MASH)Obesity
Cascade Pharmaceuticals, Inc120 enrolled12 locationsNCT07466017
Recruiting
Phase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 2
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rivus Pharmaceuticals, Inc.180 enrolled31 locationsNCT07491458
Recruiting
Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 2
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Hepatic SteatosisNonalcoholic SteatohepatitisMetabolic-Associated Steatotic Liver Disease
Hudson Biotech120 enrolled1 locationNCT07481734
Recruiting
Phase 2
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Liver FibrosisNonalcoholic Steatohepatitis
VA Office of Research and Development128 enrolled1 locationNCT05526144
Recruiting
Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis
Boston Pharmaceuticals42 enrolled35 locationsNCT06920043
Recruiting
Phase 2
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH)
The United Bio-Technology (Hengqin) Co., Ltd.156 enrolled1 locationNCT07145151
Recruiting
Phase 2
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.165 enrolled1 locationNCT06937749
Recruiting
Phase 2
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Nonalcoholic Steatohepatitis (NASH)
Polaris Group60 enrolled10 locationsNCT05842512
Recruiting
Phase 2
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Metabolic Dysfunction-Associated SteatohepatitisChronic Kidney Disease Stage 3Chronic Kidney Disease Stage 2
Enyo Pharma60 enrolled1 locationNCT06939816
Recruiting
Phase 2
A Phase 2a double-blind, randomised, placebo-controlled, parallel group study to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of GL0034 in adults with at-risk metabolic dysfunction-associated steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH)
Sun Pharmaceuticals Ltd60 enrolled1 locationACTRN12625000241437
Recruiting
Phase 2
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Type 2 Diabetes Mellitus (T2DM)Nonalcoholic Steatohepatitis
University of Florida166 enrolled1 locationNCT04501406
Recruiting
Phase 2
Soluble Fibre Supplementation in NAFLD
Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisHepatic Steatosis
McMaster University60 enrolled1 locationNCT05480696